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A B S T R A C T
Objectives: Genotyping HPV from samples tested positive to careHPV™ assay in rural and remote areas of
Brazilian territory.
Methods: A total of 5079 women were enrolled in an opportunistic screening from the Barretos Cancer Hospital,
through mobile units or ambulatory unit. All careHPV™ hr-HPV positive samples were tested by a Luminex-based
protocol in order to evaluate the HPV infecting types.
Results: Positive hr-HPV results were obtained in 10.6% (536/5068) of women. Among these cases, HPV-56 and
HPV-51 were the most common types detected in 32.3% and 31.4%, respectively. HPV-53 (20.5%), HPV-18
(18.5%), HPV-58 (17.6%), HPV-52 (16.0%) and HPV-16.6%) were the other most frequent types detected. These
frequencies represent prevalences of 2.35%, 2.12%, 2.02%, 1.84% and 1.80% respectively, within the popula-
tion studied. Regarding low-risk HPVs, HPV-6 was detected in 12.9% of the samples. The less frequent types
(< 3%) were: HPV-70, HPV-11 and HPV-26.
Conclusions: The most frequent types detected were: HPV-56, HPV-51, HPV-53, HPV-18, HPV-58, HPV-52 and
HPV-16 according to decreasing rates.
1. Introduction
Cervical cancer incidence and mortality still represents a critical
issue for Public Health authorities with almost 570 thousand new cases
and 311 thousand deaths, annually. This is particularly disturbing if
considers that the majority of these cases are found in developing and
poor countries of Africa and South America [1]. The limitations of
screening effectiveness in poor countries are usually related to the
scarcity of qualified human resources, lack of governmental planning
for organized screening programs, lower quality control in cytology
performance and absence of HPV testing, in addition to other reasons
generally related to the lower economic incoming to support prevention
cancer programs. This set of variables represents a huge barrier in the
eradication of a potentially preventable malignancy that affects mostly
women living in rural and remote areas and accentuates ethnical and
racial inequities regarding the opportunities to reduce cancer mortality
[2,3].
HPV vaccination is a well-tailored option for primary prevention
tool of HPV-related cancer. Currently, a number of evidences strongly
suggest that HPV vaccination is an important implement to reduce the
prevalence of malignancies induced by persistent HPV oncogenic types
infection in women underprivileged of medical assistance. Recently, an
elegant report conducted by Hall and colleagues indicates the possibi-
lity of cervical cancer eradication within the next 20 years in Australia
by the high-coverage vaccination and screening. The aim is to decrease
the rates to four new cases per 100,000 women per year, to consider
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cervical cancer as an extinguished problem of public health in Australia
[4]. Arbyn and co-workers at Cochrane publication demonstrated the
efficacy of HPV vaccination, which the data available about HPV vac-
cine have shown a high-certainty evidence of the protective effect of
HPV vaccines against cervical intraepithelial neoplasia in female ado-
lescents and young women aged 15 to 26 [5].
However, despite to the scientific encouragement towards vaccine
implementation, there are many restrictive elements for HPV vaccines
application with evident reluctance in many settings of the general
population, which represent a serious obstacle for HPV-induced lesions
reduction, which must be overcomes to increase the vaccine coverage
that comprise psychological, religious and/or cultural reactions [6].
The report of Muñoz and colleagues defined with robust data from
different countries the most prevalent HPV types worldwide [7]. This is
relevant because HPV vaccines were tailored based on the most im-
portant HPV types related to cervical cancer development, and the re-
sults achieved clearly demonstrated the significant contribution of these
vaccines to reduce HPV-related lesions in women cervix [8–10]. Con-
versely, some HPV types distribution are unequal worldwide, and these
variations can induce alterations on the efficacy of HPV vaccine [11].
Moreover, some specific HPV types present to biological behavioral
differences that can correspond to better or worse outcome for the
women affected with cervical cancer [12].
Considering all these facts, we sought to investigate specific HPV
types prevalence in rural and remote areas of Brazilian territory in
order to draw a map of HPV types distribution in a country with con-
tinental dimension.
2. Methods
This was a retrospective evaluation of individual HPV types pre-
valence performed within a casuistic planned for a prospective study
carried out from March to December 2010 of women attended at the
Ambulatory of Prevention Department and the mobile units of Barretos
Cancer Hospital (BCH), which assisted the Brazilian rural and remote
areas, and these samples were previously underwent to Surepath
Liquid-based Papanicolaou, and the HPV detection was performed
using the careHPV™ molecular test [3].
The project was approved by the Research Ethics Committee of the
Barretos Cancer Hospital - Pio XII Foundation, protocol number 404/
2010.
2.1. The mobile units platform
A total of 3079 volunteer women aged over than 18 were invited to
participate in a opportunistic screening available at the mobile units of
the Barretos Cancer Hospital, which assisted the states of Goiás, Minas
Gerais, Mato Grosso and São Paulo. At this stage, there was no rando-
mization of the studied group and the samples were collected by health
professionals (careHPV™ test and Liquid-based Papanicolaou test).
2.1.1. Collections carried out in mobile units
The samples collected to careHPV ™ medium were initially analyzed
in the mobile unit in ten out 63 cities visited by the unit: Mineiros (GO),
Portelândia (GO), Alto Araguaia (MT), Alto Garças (MT), Alto Taquari
(MT), Rondonópolis (MT), Pedra Preta (MT), Guiratinga (MT), São José
do Povo (MT), Itiquira (MT); totalizing over than 400 samples analyzed
in loco; the remaining samples were tested at the Research Molecular
Center of BCH.
2.2. Laboratory conditions for samples preservation
Cervico-vaginal samples tested for careHPV™ (Digene, Qiagen,
Gaithersburg, MD, USA) were maintained under at 15 °C to 30 °C for
two weeks, and/or 2 °C to 8 °C for four weeks or −20 °C for two
months. Those samples that were tested positive in the careHPV test
were maintained 2 °C to 8 °C.
2.3. DNA extraction
DNA from the positive samples maintained on the careHPV™
medium were extracted using the QIAmp MinElute Virus Vaccum kit
(Qiagen Co) according to the manufacturer's protocol. Extracted DNA
were kept in at −20 °C.
2.4. HPV genotyping
HPV positive samples using the careHPV™ test were further geno-
typed using the Luminex methodology (Luminex Corporation, TX,
USA). This methodology uses oligonucleotide probes coupled poly-
styrene beads containing two different fluorophores inside that allows
the simultaneous detection of at most 100 different specific HPV types.
In this study, probes used allowed the identifications of 21 viral types: i)
low risk: 6, 11 and 70, ii) high risk: 16, 18, 26, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 66, 68, 73 and 82. PCR reactions were performed
using the Qiagen Multiplex PCR kit (Qiagen, Dusseldorf, Germany) and
a mixture of specific biotinylated primers capable of amplifying a
fragment of the E7 gene, followed by bead-based Luminex technology
(Gheit et al., 2007; Nunes et al., 2016; Schmitt et al., 2006). Primers for
the amplification of β-globin were also added to evaluate the quality of
template DNA. For each probe, MFI (mean fluorescence intensity) va-
lues obtained when no PCR product was added to the hybridization
mixture was considered the background values. Cutoffs were computed
by adding 20 MFI to 1.1X the median background value. Whenever a
positive signal for HPV and β-globin was not obtained, the sample was
considered inadequate. Those cases in which the positive signal for HPV
was not observed, but β-globin was detected, samples were considered
negative as well.
2.5. Statistical analysis
The prevalences of HPV specific types were computed. Statistical
analysis was performed using IBM® SPSS® Statistics (Statistical Package
for Social Sciences) version 20.1 for Windows (IBM Corporation, Route
100, Somers, NY 10589) and MedCalc® version 11.1 for Windows
(Broekstraat 52, B −9030 Mariakerke, Belgium).
3. Results
Women tested positive for HPV (10.0% or n=307) using the
careHPV test showed mean age of 41.0 years. The socio-demographic
findings achieved previously did not show any statistically significant
association between HPV positivity and tobacco use, number of parities,
number of sexual partners and contraceptive [3].
3.1. HPV types
From 443 samples available for analysis, high-risk HPV was de-
tected in 369 samples, 72 were positive for high and low risk HPV si-
multaneously and 2 cases tested positive for low risk HPV (both HPV6).
Single HPVs infections were observed in 25.3% (112/443) of the
samples, two of them by low-risk HPV (HPV 6). Conversely, 74.7%
(331/443) of the samples had multiple infections solely with high-risk
types or with high- and low-risk HPVs.
HPV-56 and HPV-51 were the most common types, and were de-
tected in 32.3% and 31.4% of the samples, respectively. This represents
3.7% of HPV prevalence, considering the percentage of HPV positive
women found in this study (11.5%). Following HPV-53 (20.5%), HPV-
18 (18.5%), HPV-58 (17.6%), HPV-52 (16.0%) and HPV-16 (6%) were
the most frequent, which represents a prevalence of 2.35%, 2.12%,
2.02%, 1.84% and 1.80%, respectively, according to the percentage of
HPV positive women studied. Regarding low-risk HPVs, HPV-6 type
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was detected in about 12.9% of the samples. The less frequent detected
types (< 3%) were: HPV-70, HPV-11 and HPV-26. Fig. 1 depicts HPV
types distribution.
4. Discussion
The general positivity for high-risk HPV reported in this current
study was 10.6%: 11.5% observed in the casuistic of cases collected at
the Prevention Department of HCB and 10% detected in women ex-
amined at mobile units, respectively. Data documented by other
Brazilian studies showed positive rates ranging from 9.7% to 10.5%
[13–17]. Recently, Torres and colleagues reported HPV-DNA frequency
of 19.1% in women of remote areas of the Amazon, a region reputed as
the site with the highest indexes of HPV prevalence in the Brazilian
territory [18]. The HPV prevalence found in the current study was,
however, slightly lower than those found in previous studies, with a
prevalence superior to 15% [19] and quite similar to the prevalence of
HPV infection of 9.6% found in Malasy population [20].
HPV genotyping performed within the positive samples showed in
descending order, higher frequencies of the HPV-53, HPV-18, HPV-58,
HPV-52, and HPV-5 and HPV- HPV-16, with frequencies of detection of
32.3%, 31.4%, 20.5%, 18.5%, 17.6%, 16.0% and 15.6%, respectively.
Moreover, the overall HPV typing demonstrated that HPV types fre-
quencies is particularly different if compared to the frequencies re-
ported in literature, once HPV56, HPV51 and HPV53 were significantly
more prevalent than HPV 16 and HPV18, presumed as the more pre-
valent HPV types worldwide [7]. Interesting, however, is that fact that
previous studies, including a Canadian study, have reported a HPV DNA
detection rate of 1 to 7% of HPV-56 in CIN2 and CIN3 patients [21,22].
In a retrospective study in Brazilian Bahia State, about 14% of women
with high-grade lesions and 18% with low-grade lesions were identified
with HPV-16 and HPV-56 infection [23]. These data differ substantially
from another study carried out in the Northern region of Brazil that
place HPV-16 and HPV-18 as the most prevalent types in women in-
fected by HPV [24]. We speculate that these variations in prevalence of
HPV types are certainly particular to each different region within the
Brazilian territory; once this is a country of continental dimensions and
formed by a complex network of different cultures and races, which
may present more variations regarding HPV type regionally distribu-
tion. However, it is important to emphasize that the distribution of
different HPV types is not homogeneous worldwide. In this field,
HPV16 and HPV18 still show an important and significant protagonism
even in Brazil [25]. Some studies have demonstrated that the five most
common HPV types in the order of decreasing prevalence are HPV 16,
18, 31, 45 and 52 [26].
In addition, it is necessary to note that differences in the meth-
odologies used to detect and type HPVs can certainly influence data of
the different studies regarding HPV types prevalence.
Finally, the importance of HPV typing seems to be closed related to
the contribution that these observations can provide to the strategies of
vaccination in different regions of the world. This issue is not negligible
if one takes in account that HPV vaccination should be planned for
certain regions of the world, considering that the variation of HPV
typing could infer a bias of HPV vaccine efficacy if the most prevalent
types are not included among types selected for bivalent, quadrivalent
or nonavalent vaccine currently available in the medical arma-
mentarium. Cross-protection is presently and potentially expectable for
all of the 3 licensed HPV vaccines provide protection against HPV types
not included in the vaccines. It is well-stablished that bivalent and
quadrivalent HPV vaccines provide some level of cross-protection
against high-risk HPV types: 31, 33 and 45 HPV types. However, the
degree of cross-protection against HPV types of nonavalent vaccine is
not yet documented [27].
In conclusion, our study demonstrated that HPV types have a sig-
nificative variation prevalence in Brazilian territory; data can be im-
proved with robust increasing casuistry.
Disclosure
The careHPV ™ test kits, as well as equipment, preservation media,
consumables and brushes for molecular testing, were provided by
Qiagen® Brazil.
Fig. 1. General distribution of HPV genotypes detected in the cervicovaginal samples. The different genotypes are marked on the “Y" axis, while the frequency of the
cases (shown in percentage) are on the “X" axis.
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